Journal
LEUKEMIA & LYMPHOMA
Volume 63, Issue 9, Pages 2023-2032Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2022.2064995
Keywords
CLL; Immunotherapy; BTK inhibitors; Leukaemia
Categories
Ask authors/readers for more resources
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease, and cell-to-cell interactions in the tumor microenvironment play a significant role in the progression of the disease and the spread of CLL cells. Inhibition of BTK with BTK inhibitors has shown potential in controlling CLL clones and restoring the balance of humoral immunity.
The CLL disease course is heterogeneous with many patients never requiring treatment and some having very aggressive rapid onset disease.Innate and adaptive immune compensatory mechanisms driven by malignant cells often lead to clonal proliferation, migration and resistance to treatment in CLL. Cell-to-cell interactions occurring within the tumor Micro-environment (TME) can impact greatly on the course of the disease as well as contribute to the variable spread of CLL cells, known as spatial heterogeneity. Following evidence showing the expression of BTK on many hematopoietic cells (an exception beting T lymphocytes) has given rise to the idea that inhibition of BTK with BTK inhibitors (BTKi) such as ibrutinib can help treat CLL.As BTK has a wide variation of expression among cells the use of BTKi has been shown to not only control CLL clones but also redistribute the balance of humoral immunity back toward those of healthy control. n this review article we look at role of BTK in the pathogenesis of CLL, the use of BTKi and their effect on humoral immunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available